Earnings Call Summary | Sharecare(SHCR.US) Q1 2024 Earnings Conference
Earnings Call Summary | Sharecare(SHCR.US) Q1 2024 Earnings Conference
The following is a summary of the Sharecare, Inc. (SHCR) Q1 2024 Earnings Call Transcript:
以下是Sharecare, Inc.（SHCR）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Sharecare reported Q1 2024 revenues of approximately $91 million and adjusted EBITDA of negative $2.7 million, reflecting the impact of a dispute.
Revenue was down $25.4 million over the prior year, due to the aforementioned legal dispute.
Sharecare報告稱，2024年第一季度收入約爲9,100萬美元，調整後的息稅折舊攤銷前利潤爲負270萬美元，這反映了爭議的影響。
由於上述法律糾紛，收入比上年下降了2540萬美元。
Business Progress:
業務進展：
Despite softer macro pharma spending, Sharecare closed deals with 35 new pharma brands in Q1.
The provider channel, a profitable $120 million business, closed 75 Q1 deals, with the average deal size doubling from the prior year.
Sharecare is set to launch a new Medicaid navigation platform with its first client, Peach State Health Plan, in July 2024.
The company is discussing potential strategic transactions or a sale to enhance shareholder value, with the process anticipated to conclude within the next 30 to 45 days.
Q1 showed a $3 million gap due to cost management, however, EBITDA is expected to improve, particularly in Q3 for the provider channel and Q4 for life sciences.
Significant pipeline growth has been seen since the start of the year, with a new Head of Sales and Operations on board to improve close and success rates.
Based on numerous requests for proposals (RFPs), the enterprise business is expected to gain momentum starting in Q3.
As part of new KPI strategies, they will focus on delivering related insights about sales in coming quarters.
儘管宏觀藥業支出疲軟，但Sharecare在第一季度完成了與35個新制藥品牌的交易。
該提供商渠道是一家盈利1.2億美元的業務，第一季度完成了75筆交易，平均交易規模比上年翻了一番。
Sharecare定於2024年7月與其第一個客戶Peach State Health Plan一起推出新的醫療補助導航平台。
該公司正在討論潛在的戰略交易或出售以提高股東價值，該過程預計將在未來30至45天內結束。
由於成本管理，第一季度出現300萬美元的缺口，但是，預計息稅折舊攤銷前利潤將有所改善，尤其是在供應商渠道的第三季度和生命科學的第四季度。
自年初以來，管道已出現顯著增長，新任銷售和運營主管上任，以提高成交率和成功率。
根據大量徵求建議書（RFP），預計企業業務將從第三季度開始獲得動力。
作爲新的關鍵績效指標戰略的一部分，他們將專注於提供有關未來幾個季度的銷售的相關見解。
More details: Sharecare IR
更多詳情： Sharecare IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。